ENOVIS CORP (ENOV) Stock Price, Forecast & Analysis
USA - New York Stock Exchange - NYSE:ENOV - US1940141062 - Common Stock
ENOV Key Statistics, Chart & Performance
The current stock price of ENOV is 30.31 USD. In the past month the price decreased by -5.25%. In the past year, price decreased by -37.9%.
ENOV Latest News, Press Relases and Analysis
ENOV Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABT | ABBOTT LABORATORIES | 25.76 | 223.72B | ||
| ISRG | INTUITIVE SURGICAL INC | 66.69 | 205.85B | ||
| BSX | BOSTON SCIENTIFIC CORP | 34.22 | 149.60B | ||
| SYK | STRYKER CORP | 28.27 | 142.33B | ||
| IDXX | IDEXX LABORATORIES INC | 59.95 | 60.48B | ||
| BDX | BECTON DICKINSON AND CO | 13.45 | 55.58B | ||
| EW | EDWARDS LIFESCIENCES CORP | 33.75 | 50.34B | ||
| RMD | RESMED INC | 25.76 | 37.22B | ||
| GEHC | GE HEALTHCARE TECHNOLOGY | 17.57 | 36.73B | ||
| DXCM | DEXCOM INC | 33.62 | 24.52B | ||
| PODD | INSULET CORP | 71.51 | 22.99B | ||
| ZBH | ZIMMER BIOMET HOLDINGS INC | 12.06 | 19.32B |
Related stock screener links
About ENOV
Company Profile
Enovis Corp. operates as a medical technology growth company. The company is headquartered in Wilmington, Delaware and currently employs 7,367 full-time employees. The company went IPO on 2008-05-08. The company is focused on developing clinically differentiated solutions by manufacturing and distributing high-quality medical devices with a range of products used for reconstructive surgery, rehabilitation, pain management and physical therapy. The company operates through two segments: Prevention & Recovery and Reconstructive. The Prevention & Recovery segment provides orthopedic and recovery science solutions, including devices, software, and services across the patient care continuum from injury prevention to rehabilitation after surgery, injury, or from degenerative diseases. The Prevention & Recovery products are marketed under several brand names, such as DJO. The Reconstructive segment provides surgical implant solutions, offering a comprehensive suite of reconstructive joint products for the hip, knee, shoulder, elbow, foot, ankle, and finger and surgical productivity tools. The company also operates a Enovis Growth eXcellence business system (EGX).
Company Info
ENOVIS CORP
2711 Centerville Road, Suite 400
Wilmington DELAWARE US
Employees: 7367
Phone: 13022529160
ENOVIS CORP / ENOV FAQ
What does ENOVIS CORP do?
Enovis Corp. operates as a medical technology growth company. The company is headquartered in Wilmington, Delaware and currently employs 7,367 full-time employees. The company went IPO on 2008-05-08. The company is focused on developing clinically differentiated solutions by manufacturing and distributing high-quality medical devices with a range of products used for reconstructive surgery, rehabilitation, pain management and physical therapy. The company operates through two segments: Prevention & Recovery and Reconstructive. The Prevention & Recovery segment provides orthopedic and recovery science solutions, including devices, software, and services across the patient care continuum from injury prevention to rehabilitation after surgery, injury, or from degenerative diseases. The Prevention & Recovery products are marketed under several brand names, such as DJO. The Reconstructive segment provides surgical implant solutions, offering a comprehensive suite of reconstructive joint products for the hip, knee, shoulder, elbow, foot, ankle, and finger and surgical productivity tools. The company also operates a Enovis Growth eXcellence business system (EGX).
Can you provide the latest stock price for ENOVIS CORP?
The current stock price of ENOV is 30.31 USD. The price decreased by -0.39% in the last trading session.
What is the dividend status of ENOVIS CORP?
ENOV does not pay a dividend.
How is the ChartMill rating for ENOVIS CORP?
ENOV has a ChartMill Technical rating of 0 out of 10 and a ChartMill Fundamental rating of 4 out of 10.
Is ENOVIS CORP (ENOV) stock a good buy?
This depends on your investment goals. Check the Technical and Fundamental Analysis tabs for insights on ENOV.
What is the outstanding short interest for ENOVIS CORP?
The outstanding short interest for ENOVIS CORP (ENOV) is 13.73% of its float.
ENOV Technical Analysis
ENOV Fundamental Analysis
ChartMill assigns a fundamental rating of 4 / 10 to ENOV. There are concerns on the financial health of ENOV while its profitability can be described as average.
ENOV Financial Highlights
Over the last trailing twelve months ENOV reported a non-GAAP Earnings per Share(EPS) of 3.33. The EPS increased by 26.14% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -30.84% | ||
| ROE | -67.66% | ||
| Debt/Equity | 0.66 |
ENOV Forecast & Estimates
16 analysts have analysed ENOV and the average price target is 51 USD. This implies a price increase of 68.26% is expected in the next year compared to the current price of 30.31.
For the next year, analysts expect an EPS growth of 12.58% and a revenue growth 7.28% for ENOV